Blurbs

Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (ARWR), Xilio Therapeutics (XLO) and LHC Group (LHCG)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Arrowhead Pharmaceuticals (ARWRResearch Report), Xilio Therapeutics (XLOResearch Report) and LHC Group (LHCGResearch Report).

Arrowhead Pharmaceuticals (ARWR)

In a report issued on March 10, Mani Foroohar from Leerink Partners maintained a Hold rating on Arrowhead Pharmaceuticals. The company’s shares closed last Monday at $40.34, close to its 52-week low of $39.42.

According to TipRanks.com, Foroohar ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -21.5% and a 33.8% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, Recursion Pharmaceuticals, and Rocket Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arrowhead Pharmaceuticals with a $89.83 average price target.

See the top stocks recommended by analysts >>

Xilio Therapeutics (XLO)

In a report released today, Michael King from H.C. Wainwright reiterated a Buy rating on Xilio Therapeutics, with a price target of $36.00. The company’s shares closed last Monday at $7.72, close to its 52-week low of $7.00.

According to TipRanks.com, King is a 4-star analyst with an average return of 7.5% and a 42.0% success rate. King covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Intellia Therapeutics, and Werewolf Therapeutics.

Currently, the analyst consensus on Xilio Therapeutics is a Moderate Buy with an average price target of $36.00.

LHC Group (LHCG)

Leerink Partners analyst Whit Mayo maintained a Hold rating on LHC Group on March 10 and set a price target of $150.00. The company’s shares closed last Monday at $133.82.

According to TipRanks.com, Mayo is a 4-star analyst with an average return of 8.2% and a 56.2% success rate. Mayo covers the Healthcare sector, focusing on stocks such as Airsculpt Technologies, Inc., Privia Health Group, and Oak Street Health.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for LHC Group with a $167.27 average price target, implying a 22.4% upside from current levels. In a report issued on February 25, Barclays also maintained a Hold rating on the stock with a $154.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ARWR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos